DDX17 (DEAD-Box Helicase 17), also known as p72, is a member of the highly conserved DEAD-box RNA helicase family. DDX17 functions as an ATP-dependent RNA helicase with critical roles in transcription regulation, alternative splicing, microRNA processing, and stress response pathways. DDX17 has emerging importance in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD) through its roles in RNA metabolism, stress granule dynamics, and protein homeostasis. [@jankowsky2011]
| Property |
Value |
| Gene Symbol |
DDX17 |
| Full Name |
DEAD-Box Helicase 17 |
| Chromosomal Location |
22q11.21 |
| NCBI Gene ID |
16532 |
| Ensembl ID |
ENSG00000146001 |
| UniProt ID |
Q9NR11 |
| Property |
Value |
| Protein Name |
DDX17 (p72) |
| Molecular Weight |
~72 kDa |
| Amino Acids |
610 amino acids |
| Subcellular Localization |
Nucleus, cytoplasm |
| Protein Family |
DEAD-box helicase family |
DDX17 possesses ATP-dependent RNA unwinding activity through its conserved helicase core. [@linder2011]
DDX17 functions as a transcriptional coactivator for nuclear hormone receptors.
As part of the spliceosome, DDX17 regulates alternative exon inclusion.
DDX17 participates in primary microRNA processing.
DDX17 has been directly implicated in ALS pathogenesis: [@kamelgarn2018]
- DDX17 mutations identified in familial and sporadic ALS patients
- Alters stress granule dynamics
- Impaired RNA granule clearance in ALS models
- Stress granule dysregulation: DDX17 localizes to stress granules under cellular stress
- RNA processing defects: Loss-of-function mutations impair proper stress granule disassembly
- TDP-43 pathology: DDX17 interacts with TDP-43, a key ALS protein
- Translation repression: Alters translational control in motor neurons
- Missense mutations: Several DDX17 missense variants identified in ALS cohorts
- Splice variants: Aberrant splicing of DDX17 transcripts in ALS brain
- Co-aggregation: DDX17 found in ALS inclusions
DDX17 involvement in PD: [@geng2020]
- Interacts with alpha-synuclein
- Regulates LRRK2 kinase activity
- Modulates mitochondrial function
DDX17 directly regulates α-synuclein expression:
- Transcriptional control: DDX17 affects SNCA transcription
- mRNA stability: Modulates alpha-synuclein mRNA half-life
- Translation regulation: Controls SNCA mRNA translation
- Feedback inhibition: α-Synuclein can inhibit DDX17 function
DDX17 interacts with LRRK2, the most common PD-associated kinase:
- Kinase regulation: DDX17 modulates LRRK2 activity
- Substrate targeting: May serve as LRRK2 substrate
- Pathogenic pathways: LRRK2-mediated phosphorylation altered
In AD:
- Global RNA processing alterations in AD brain
- Connection to tau pathology
- Effects on neuronal plasticity genes
AD neurons show widespread RNA processing abnormalities:
- Alternative splicing: Aberrant splicing patterns in AD
- microRNA dysregulation: Altered miRNA processing
- Transport defects: Impaired RNA transport to synapses
DDX17 interacts with tau:
- Tau phosphorylation: May affect tau kinase pathways
- Aggregation: Evidence for DDX17 in tau aggregates
- Clearance: Role in tau turnover mechanisms
DDX17 shows region and cell-type specific expression in cortex, hippocampus, basal ganglia, substantia nigra.
- Neurons: High expression in pyramidal neurons and dopaminergic neurons
- Microglia: Moderate expression, increases in activated states
- Astrocytes: Lower baseline, reactive changes in neurodegeneration
- Oligodendrocytes: Present, affects myelination
| Brain Region |
DDX17 Expression |
Relevance |
| Cerebral Cortex |
High |
AD vulnerability |
| Hippocampus |
High |
Memory circuits |
| Substantia Nigra |
High |
PD vulnerability |
| Spinal Cord |
High |
ALS motor neurons |
| Cerebellum |
Moderate |
Motor coordination |
DDX17 uses ATP hydrolysis to unwind RNA secondary structures:
- Helicase core: Conserved helicase domains ( motifs I, II, III, IV, V, VI)
- Substrate specificity: Prefers specific RNA structures
- Directionality: 3' to 5' unwinding
- Coupled reactions: Often coupled to ATPase activity
DDX17 localizes to stress granules (SGs):
- Stress response: Recruited to SGs under various stresses
- mRNA sequestration: Temporarily stores translationally arrested mRNAs
- Liquid-liquid phase separation: SG formation via LLPS
- Disassembly: Normally disassembled after stress resolution
DDX17 functions as coactivator:
- Nuclear receptors: Binds to nuclear hormone receptors
- Histone modification: Affects chromatin state
- Mediator complex: Part of transcriptional complexes
- Enhancer RNA: Processes eRNAs from enhancers
| Strategy |
Approach |
Stage |
Challenges |
| Helicase modulation |
Modulate activity |
Research |
Specificity |
| Stress granule therapy |
Normalize dynamics |
Research |
Delivery |
| Gene therapy |
Restore expression |
Preclinical |
Safety |
| Small molecules |
Target protein-protein interactions |
Discovery |
Selectivity |
¶ Domain Structure
DDX17 contains several conserved domains:
| Domain | Residues | Function |
|--------|---------|----------|
| N-terminal domain | 1-150 | Regulatory |
| Helicase core | 151-450 | ATP-dependent helicase |
| C-terminal domain | 451-610 | RNA binding |
| C-terminal extension | 540-610 | Specificity |
The helicase core contains conserved motifs:
- Motif I (Walker A): ATP binding - GxxxxGKST
- Motif II (Walker B): ATP hydrolysis - DEAD
- Motif III: Signal propagation
- Motif IV: RNA interaction
- Motif V: Coupling
- Motif VI: ATP release
| Property |
Value |
| ATPase Km |
~1 mM |
| Helicase activity |
ATP-dependent |
| Unwinding rate |
~100 bp/s |
| Processivity |
Moderate |
| Salt optimum |
50-150 mM KCl |
DDX17 undergoes various PTMs:
- Phosphorylation: Serine/threonine kinases
- Methylation: Arginine methyltransferases
- Acetyltransferase: p300/CBP
- SUMOylation: SUMO proteins
- Ubiquitination: Degradation signals
DDX17 interacts with numerous proteins:
| Partner |
Interaction |
Functional consequence |
| TDP-43 |
Direct binding |
Stress granule dynamics |
| FUS |
Direct binding |
ALS pathogenesis |
| p72 |
Dimerization |
Activity regulation |
| SIRT1 |
Deacetylase |
Function modulation |
| SMN complex |
Assembly |
snRNP biogenesis |
DDX17 has potential as biomarker:
- Blood levels: Altered in neurodegenerative disease
- CSF detection: Measurable in cerebrospinal fluid
- Cellular models: iPSC-derived neurons
- Panel testing: Included in ALS/PD gene panels
- Interpretation: Pathogenic vs. benign variants
- Family testing: Cascade screening
Direct targeting strategies:
- Helicase modulators: Modify activity
- Protein-protein interaction inhibitors: Block pathogenic interactions
- Gene therapy: Supply functional DDX17
- Anti-sense oligonucleotides: Reduce toxic variants
| Trial |
Compound |
Stage |
Target |
| None current |
- |
- |
DDX17 |
DDX17 is highly conserved across species:
| Species |
Ortholog |
Identity |
| Human |
DDX17 |
100% |
| Mouse |
Ddx17 |
95% |
| Zebrafish |
ddx17 |
78% |
| Drosophila |
p72 |
65% |
| C. elegans |
hel-1 |
55% |
The conservation suggests essential cellular functions.
DDX17 is a multifunctional RNA helicase with emerging roles in neurodegeneration. Key points:
- Essential enzyme: Central to RNA metabolism
- Disease associations: ALS, PD, and AD
- Therapeutic target: Multiple approaches in development
- Biomarker potential: Diagnostic and prognostic utility
- research priority: Active investigation areas
- Genetic screening: Identify additional DDX17 variants
- Mechanism studies: Elucidate DDX17-aggregation links
- Therapeutic development: Identify druggable targets
- Biomarkers: DDX17 as disease biomarker
- Model systems: Develop better cellular models
| Approach |
Status |
Description |
| Helicase activators |
Research |
Enhance DDX17 activity |
| Stress granule modulators |
Research |
Normalize stress granule dynamics |
| Gene therapy |
Research |
Deliver functional DDX17 |
- Linder & Jankowsky, From unwinding to clamping (2011)
- Jankowsky, RNA helicases at work (2011)
- Kamelgarn et al., DDX17 in ALS (2018)
- Geng et al., DDX17 in Parkinson's Disease (2020)